Moody Aldrich Partners LLC Sells 7,969 Shares of Haemonetics Co. (NYSE:HAE)

Moody Aldrich Partners LLC cut its stake in shares of Haemonetics Co. (NYSE:HAE) by 26.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,957 shares of the medical instruments supplier’s stock after selling 7,969 shares during the quarter. Moody Aldrich Partners LLC’s holdings in Haemonetics were worth $2,642,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Quadrant Capital Group LLC lifted its holdings in shares of Haemonetics by 708.8% during the first quarter. Quadrant Capital Group LLC now owns 647 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 567 shares during the period. Retirement Systems of Alabama lifted its holdings in shares of Haemonetics by 0.3% during the second quarter. Retirement Systems of Alabama now owns 66,603 shares of the medical instruments supplier’s stock valued at $8,015,000 after acquiring an additional 205 shares during the period. Jackson Square Partners LLC lifted its holdings in shares of Haemonetics by 12.8% during the first quarter. Jackson Square Partners LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $144,838,000 after acquiring an additional 187,950 shares during the period. Marshall Wace North America L.P. lifted its holdings in shares of Haemonetics by 181.1% during the first quarter. Marshall Wace North America L.P. now owns 6,859 shares of the medical instruments supplier’s stock valued at $600,000 after acquiring an additional 4,419 shares during the period. Finally, Oakbrook Investments LLC bought a new position in shares of Haemonetics during the second quarter valued at $439,000. 98.53% of the stock is owned by institutional investors.

A number of brokerages have issued reports on HAE. Morgan Stanley lifted their price objective on Haemonetics from $128.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday. Raymond James lifted their price objective on Haemonetics from $110.00 to $150.00 and gave the company an “outperform” rating in a report on Wednesday. Jefferies Financial Group lifted their price objective on Haemonetics from $125.00 to $140.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Zacks Investment Research raised Haemonetics from a “sell” rating to a “hold” rating in a report on Tuesday, April 9th. Finally, TheStreet raised Haemonetics from a “c+” rating to a “b-” rating in a report on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Haemonetics has an average rating of “Buy” and an average price target of $136.83.

In related news, CFO William P. Mr. Burke sold 411 shares of Haemonetics stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $103.38, for a total value of $42,489.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Simon sold 5,008 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $121.79, for a total value of $609,924.32. The disclosure for this sale can be found here. Insiders sold 105,754 shares of company stock valued at $10,455,709 over the last ninety days. 1.32% of the stock is currently owned by company insiders.

Haemonetics stock opened at $131.24 on Wednesday. The firm has a 50-day simple moving average of $120.99. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.44 and a quick ratio of 1.62. Haemonetics Co. has a 12-month low of $80.24 and a 12-month high of $132.72. The company has a market capitalization of $6.23 billion, a PE ratio of 54.91, a price-to-earnings-growth ratio of 3.08 and a beta of 0.82.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.18. Haemonetics had a return on equity of 18.88% and a net margin of 5.69%. The business had revenue of $238.50 million during the quarter, compared to analysts’ expectations of $236.82 million. During the same period in the previous year, the business posted $0.59 earnings per share. The firm’s revenue for the quarter was up 4.0% compared to the same quarter last year. Equities analysts predict that Haemonetics Co. will post 2.93 EPS for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.